Parabilis Medicines insider purchases have sparked a flurry of interest in the stock market, particularly as the company’s shares rose by an impressive 5.3% in premarket trading on Tuesday.This surge is largely attributed to significant buying activities by top executives, including Director Alan Sebulsky, who acquired 12,500 shares at $20 each, as reported in a…

Continue Reading